RestorGenex Corp. (NASDAQ:DFFN) is set to issue its quarterly earnings data on Monday, November 13th.
Shares of RestorGenex Corp. (NASDAQ DFFN) opened at $1.37 on Friday. RestorGenex Corp. has a one year low of $1.27 and a one year high of $15.50.
COPYRIGHT VIOLATION NOTICE: “RestorGenex Corp. (DFFN) Scheduled to Post Quarterly Earnings on Monday” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2017/11/12/restorgenex-corp-dffn-scheduled-to-post-quarterly-earnings-on-monday.html.
About RestorGenex Corp.
Diffusion Pharmaceuticals Inc, formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company’s lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments.
Receive News & Ratings for RestorGenex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RestorGenex Corp. and related companies with MarketBeat.com's FREE daily email newsletter.